Day: March 25, 2025

NEWARK, Del., March 25, 2025 (GLOBE NEWSWIRE) — Artesian Resources Corporation (Nasdaq: ARTNA), a leading provider on the Delmarva Peninsula of water and wastewater services, and a number of other related business services, today announced earnings results for the fourth quarter and year ended December 31, 2024.   “I am pleased to report improved earnings in 2024 as we remain focused on critical investments in infrastructure and managing costs,” stated President and CEO, Nicholle Taylor. “In 2024 alone we invested $45.9 million in infrastructure, as we remain committed to providing customers with water and wastewater systems that are resilient and protective of public health and the environment.” Year-End Results Net income for the year ended December 31, 2024 was $20.4 million, a $3.7 million, or 22.1%, increase compared to net...

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) Completed Studies to Support Process Optimization through Cell Line Switch for Budoprutug and Filed Additional Patent Applications to Further Strengthen Intellectual Property Position Expanded Pipeline to Include CLYM116, an Anti-APRIL (A PRoliferation-Inducing Ligand) Monoclonal Antibody for Treatment of IgA Nephropathy (IgAN) Appointed Perrin Wilson, Ph.D. as Chief Business Officer Ended 2024 in a Strong Financial Position, with Cash Runway Expected Through 2027 WELLESLEY HILLS, Mass., March 25, 2025 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for...

TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the...

Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027 Phase 3 LEVEL Study Expansion Increases Statistical Power; Enrollment Completion Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., March 25, 2025 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial results for the year ended December 31, 2024 and provided an update on its recent corporate progress. “The past year has...

Management to Host Conference Call Tomorrow at 8:30 a.m. Eastern Time NORWALK, Conn., March 25, 2025 (GLOBE NEWSWIRE) — Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, is reporting financial results for the three months and twelve months ended December 31, 2024. Q4 2024 Financial Highlights (vs. Q4 2023):Net sales were $9.7 million compared to $11.7 million. Gross profit increased more than 5x to $2.9 million compared to $0.5 million, with gross margin of 30.0% compared to 4.0%. This includes one-time charges in the prior-year period related to a non-cash packaging inventory valuation adjustment and a provision for product hold related to the Company’s swing-lid program. Delivery and handling costs were reduced by 10% to $3.00 per case. Selling,...

Full year net revenue was $200.9 million, a 25% increase year-over-year Fourth quarter revenue was $53.0 million, up 31% year-over-year reflecting over 20% growth in all three business segments Fourth quarter adjusted EBITDA was $9.0 million, up 139% year-over-year Biomass production was 165,074 pounds in the fourth quarter, up 60% year-over-year Fourth quarter cost per equivalent dry pound of production was $110, down from $121 per pound for the equivalent period last year Fourth quarter consolidated gross profit margin was 43%, compared to 45% in Q4 2023 Cash and restricted cash balance rose to $36.9 million on December 31, 2024, compared to $35.1 million on September 30, 2024 Conference call to be held today March 25, 2025, at 5:00 p.m. ETLONG BEACH, Calif. and TORONTO, March 25, 2025 (GLOBE NEWSWIRE) — Glass House Brands...

GRAPEVINE, Texas, March 25, 2025 (GLOBE NEWSWIRE) — GameStop Corp. (NYSE: GME) (“GameStop” or the “Company”) today released financial results for the fourth quarter and fiscal year ended February 1, 2025. The Company’s consolidated financial statements, including GAAP and non-GAAP results, are below. The Company’s Form 10-K and supplemental information can be found at https://investor.gamestop.com. FOURTH QUARTER OVERVIEWNet sales were $1.283 billion for the fourth quarter, compared to $1.794 billion in the prior year’s fourth quarter. Selling, general and administrative (“SG&A”) expenses were $282.5 million for the fourth quarter, compared to $359.2 million in the prior year’s fourth quarter. Net income was $131.3 million for the fourth quarter, compared to net income of $63.1 million for the prior year’s fourth...

IRVINE, Calif., March 25, 2025 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2024 and introduced its annual guidance for the year ending December 31, 2025. Fourth Quarter 2024 Financial Highlights & Key MetricsNet sales of $20.4 million, up 145% compared to $8.4 million in the fourth quarter of 2023.Durable Medical Equipment (DME) channel net sales of $18.1 million, up 127% compared to $7.9 million in the fourth quarter of 2023. Pharmacy Benefit Plan (PBP) channel net sales of $2.4 million, up 491% compared to $0.4 million in the fourth quarter of 2023.Gross margin of 57.2%, down 344 basis points compared to 60.6% in the fourth quarter of 2023. Installed...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and Novel Mechanism of Action Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2024. “We continue to advance our selective ITK inhibitor, soquelitinib, in a range of diseases,” said Richard A. Miller, M.D., co-founder,...